Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nova Eye Medical ( (AU:EYE) ) just unveiled an announcement.
Nova Eye Medical Limited held its Annual General Meeting on 27 November 2025, where all resolutions were carried with significant majorities. The resolutions included the adoption of the remuneration report, the re-election of directors Victor Previn and Daniel Webb, and the approval of an employee incentive plan. The approval of these resolutions reflects strong shareholder support and is likely to positively impact the company’s governance and operational strategies.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
More about Nova Eye Medical
Nova Eye Medical Limited operates in the medical technology industry, focusing on developing and commercializing innovative treatment solutions for eye diseases. The company is dedicated to improving patient outcomes through advanced ophthalmic technologies.
Average Trading Volume: 306,004
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$35.6M
See more data about EYE stock on TipRanks’ Stock Analysis page.